Mycamine (micafungin) is a systemic antimycotic indicated for invasive candidiasis, oesophageal candidiasis and prophylaxis of candida infection.

Mycamine inhibits the synthesis of 1,3-B-D-glucan, an essential component of the fungal cell wall.

Treatment must be initiated by a specialist and the decision to use Mycamine should take into account a potential risk of developing liver tumours. Liver function must be carefully monitored throughout treatment.

Treatment indications:

  • Invasive candidiasis in adults and children.
  • Oesophageal candidiasis in patients aged >16 years where iv therapy is appropriate.
  • Prophylaxis of candida infection in adults and children undergoing allogeneic haematopoietic stem cell transplantation or patients expected to have neutropenia for >10 days.

View Mycamine drug record

Further information: Astellas

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more